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FeatureBacterial infections resistant to antibiotics kill 23,000 people per year in the US 
alone, a recent report warns. This crisis is man-made, as misuse of the miracle 
drugs over decades has thrown away their life-saving potential. Michael Gross 
reports. 
Antibiotics in crisis Critical mass: Bacteria with multiple drug resistance kill around 23,000 people per year in the 
US alone, and a similar number across Europe. That figure corresponds to the capacity of the 
Arthur Ashe Stadium in New York shown here, or the O2 Arena in London. (Photo: Wikimedia 
Commons/davidwboswell)The US Food and Drugs Administration 
once proposed a regulation to ban the 
use of three antibiotics in cattle feed, 
where they act to promote growth, not 
to fight disease. The industry opposed 
the measure and won. That was 35 
years ago. The practice is still being 
used today, even though the loss of 
efficient antibiotics and the return of 
infectious diseases is now a clear and 
present danger to the lives of millions. 
Former editor-in-chief of Science 
magazine Donald Kennedy was involved 
in the FDA proposal back then and has 
recently revisited the issue in an editorial 
(Science (2013) 342, 777). Around three 
quarters of antibiotics sold in the US 
are for veterinary use, says Kennedy. 
While inappropriate prescriptions for 
and inadequate use by human patients 
also contribute to the problem, Kennedy 
argues that “antibiotic resistance will 
be solved only when we end the use 
(or rather, the abuse) of these agents in 
veterinary medicine.” 
Kennedy now sees new hope, as 
a new FDA draft guideline, known as 
Guidance #213, could be implemented 
soon. It would be none too early, as a 
recent report from the US Centers for 
Disease Control and Prevention (CDC) 
describes the dramatic extent of the 
antibiotics crisis (Antibiotic Resistance 
Threats in the United States 2013, 
http://www.cdc.gov/drugresistance/
threat-report-2013/) and current 
research and development offers only 
very few and faint silver linings. 
Antibiotics apocalypse 
The report, aiming to provide crucial 
information on the dangers of spreading 
resistance traits to policy makers, 
medical professionals and patients 
alike, distinguishes three threat levels — 
namely urgent, serious, and concerning. 
Between them, multidrug-resistant 
bacteria kill 23,000 people per year in 
the US, the report estimates. The latest 
figures for Europe, at 25,000 casualties, 
are very similar. 
Among the urgent threats 
are carbapenem-resistant Enterobacteriaceae (CRE), a group of 
bacteria that have become resistant 
against “all or nearly all” of today’s 
antibiotics, including carbapenems, 
which are typically reserved as an 
antibiotic of last resort. If infections 
enter the bloodstream, there is only 
a 50% survival rate. The two most 
common groups of CRE, Klebsiella and 
Escherichia coli, account for around 
600 deaths in the US per year. 
Another antibiotic-resistant pathogen 
is the gonorrhoea agent, Neisseria 
gonorrhoeae. While not normally 
fatal, gonorrhoea spreads easily and 
can cause severe complications in 
reproductive functions. In response 
to emerging resistance problems, 
the CDC has updated its treatment 
guidelines. It now recommends only 
ceftriaxone plus either azithromycin or 
doxycycline as first-line treatment for 
gonorrhoea.The third and final ‘urgent’ threat 
is Clostridium difficile, a bacterium 
that commonly invades the intestines 
of patients whose own commensal 
bacteria have been weakened 
by treatment with antibiotics. As 
antibiotics are the root of the problem 
here, they cannot easily be used to 
fight C. difficile invasion — repeated 
application will increase the risk that 
the infection becomes intractable. As 
an experimental therapy, some doctors 
have started treating this problem by 
transferring gut microbiota (Curr. Biol. 
(2013), 23, R359–R362).
C. difficile infection causes life-
threatening diarrhoea and is now 
responsible for 14,000 deaths a year 
in the US alone. The mortality has 
increased dramatically since the year 
2000, when a new strain emerged that 
is resistant to antibiotics commonly 
used to treat other infections. However, 
in contrast to the other diseases 
discussed in the report, resistance to 
the drugs used against this pathogen is 
not a problem yet. Therefore, the CDC 
has not included the 14,000 deaths it 
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Serious threat: Extended spectrum beta-lactamase-producing strains of Enterobacteriaceae, 
including Klebsiella species and E. coli, are responsible for around 1,700 deaths per year in the 
US. (Photo: courtesy of CDC http://www.cdc.gov) causes in its estimate of 23,000 victims 
of antibiotics resistance. 
The drug-resistant threats classed 
as serious include the much publicised 
‘hospital superbug’ MRSA (methicillin-
resistant Staphylococcus aureus) along 
with resistant strains of Streptococcus, 
Salmonella, Enterobacteriaceae, and 
tuberculosis, among others. MRSA 
alone is responsible for almost half of 
the death toll, with 11,285 deaths per 
year in the US alone. However, the 
incidence of healthcare-associated 
MRSA infections seems to be declining, 
as preventive hygiene measures in 
hospitals are showing effect. 
Another serious threat is 
Streptococcus pneumoniae, which 
causes 7,000 deaths per year in 
the US and is the main cause of 
bacterial pneumonia and meningitis 
there. Around 1,700 deaths per 
year are blamed on a group of 
Enterobacteriaceae that carry a broad 
spectrum beta-lactamase enzyme, 
which enables them to overcome all 
antibiotics of the penicillin and the 
cephalosporin groups. 
Tuberculosis is listed as serious in 
the US, but is one of the most urgent 
resistance problems worldwide. The 
2013 tuberculosis report of the WHO 
estimates that in 2012 170,000 people 
worldwide died of multidrug-resistant 
tuberculosis. 
Apart from the return of infectious 
diseases that we had thought we 
put behind us, the weakening of our antibiotic defence also has a knock-
on effect on the safety of medical 
procedures with intrinsic infection 
risks, including major surgery, organ 
transplant, chemotherapy for cancer, 
and premature births, as Ramanan 
Laxminarayan and colleagues warn in 
a recent review of the global situation 
of antibiotics resistance (Lancet Infect. 
Dis. (2013) 13, 1057–1098).
Urgent measures
In its report, the CDC recommends 
four “core actions” that can help to 
stop antibiotic resistance, including: 
prevention of infection through 
hygiene, immunisation, and correct 
use of antibiotics; improved monitoring 
infectious diseases as a foundation for 
strategic disease prevention; improving 
antibiotic “stewardship” and stopping 
misuse in medicine and in agriculture; 
and research to develop new drugs 
and diagnostics. 
On the stewardship issue, the report 
notes that: “Perhaps the single most 
important action needed to greatly slow 
down the development and spread 
of antibiotic-resistant infections is to 
change the way antibiotics are used. 
Up to half of antibiotic use in humans 
and much of antibiotic use in animals 
is unnecessary and inappropriate and 
makes everyone less safe.”
The sheer number of antibiotics 
prescriptions to patients in the US 
gives an indication that there remains 
a lot of work to be done in this respect. In quite a few states of the US, the 
average number of antibiotics courses 
prescribed per year exceeds the 
population size, so there is more than 
one treatment handed out per year per 
head. Intriguingly, the prescription habits 
seem to vary with latitude. Doctors 
in the states lining the West Coast 
prescribe the least antibiotics, while 
those in a strip running from the Great 
Lakes down to the Gulf Coast states 
are in the highest-prescribing category. 
Investigations into the underlying 
reasons are currently under way. 
Perhaps the most worrying aspect 
of the excessive prescription of 
antibiotics is that it is committed by 
medical practitioners who should 
really know better by now. If even 
the doctors fail to handle antibiotics 
correctly, what hope is there that the 
patients do so? 
Appealing to healthcare professionals 
to improve their stewardship, the 
report notes that there are tangible 
benefits for all sides — patients are 
more likely to be cured of their illnesses 
while suffering fewer side effects and 
healthcare providers can save costs by 
only administering the right drugs in the 
right dose. Moreover, good stewardship 
is necessary to preserve efficient 
antibiotics for future use, as there is an 
acute shortage of new drugs becoming 
available. 
Part of the problem with the spread 
of antibiotics resistance is that the 
discovery of new types of antibiotics 
has dried up in the last decades. 
Twenty new classes of antibiotics were 
discovered before 1980, but only two 
since then. The report offers neither 
explanations nor solutions to this 
fundamental pipeline problem, but a 
few potential alternatives to antibiotics 
are already being investigated. 
Silver linings 
One promising way of making 
more of the limited number of 
antibiotics available is to use them in 
combinations and sequences designed 
to kill off bacteria more efficiently and 
to avoid resistance, rather than just 
picking a different drug at random if the 
first didn’t work. Lejla Imamovic and 
Morten Sommer from the Technical 
University of Denmark have developed 
what they call “collateral sensitivity 
networks” for bacterial pathogens. The 
phenomenon of collateral sensitivity is 
simply based on the observation that 
specific adaptations making a bacterial 
strain resistant to one type of antibiotic 
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Massive misuse: The majority of antibiot-
ics sold in the US are used in agriculture, 
where they are typically used to promote 
growth rather than to fight dangerous dis-
eases. Although this practice was identified 
as a contributor to antibiotics resistance 
decades ago, it has continued to this day. 
(Photo: Nerys H. Gross.)come at a fitness cost and may make it 
more sensitive to another. 
Working with E. coli, for instance, 
Imamovic and Sommer could show 
that cycling of the drugs gentamicin 
and cefuroxime led to efficient 
eradication of the bacteria, including 
those that were resistant to one of the 
drugs. While this report is only a proof 
of principle, the authors anticipate 
that rationally designed deployment of 
already approved drugs in combination 
could improve the treatment of a 
number of diseases where evolved 
resistance is a problem. 
Two other emerging approaches 
target the ability of bacteria to 
establish colonies in their host, and to 
persist in an inactive state. In a recent 
perspective article, Kaelyn Wilke and 
Erin Carlson from Indiana University in 
Bloomington, US, surveyed research 
targeting the bacterial histidine 
kinases, which are important signalling 
stations in the communications 
between bacteria invading a host (Sci.
Trans. Med. (2013) 5, 203ps12). 
While this approach has already 
been tried in the 1990s, the authors 
argue that the compounds tried then 
were unsuitable for bacterial targets. 
Moreover, as pathogenic bacteria 
tend to rely on this kind of signalling 
for multiple functions crucial for their 
success in establishing an infection, 
successful histidine kinase inhibitors 
could disrupt so many functions at 
once that there would be no escape 
route for the pathogens. 
Another problem affecting the 
success of existing antibiotics is 
the ability of some bacterial species 
to generate ‘persister’ populations 
consisting of a stochastically selected, 
genetically identical subpopulation 
that goes into an inactive state and is 
thus resilient to all drug treatments that 
target cell division or metabolism. 
Recently, the group of Kim Lewis 
at Northeastern University in Boston, 
US, could demonstrate that a group of 
substances known as acyldepsipeptides 
can exterminate such persister cells 
(Nature (2013) 503, 365–370). These 
molecules enter the cell and wedge 
open the entrance to a protease named 
ClpP. Like the proteasome, this protease 
adopts a barrel shape with the active 
centre on the inside. Strict regulation 
of access to the cavity stops it from 
degrading proteins indiscriminately. 
By opening access to this reaction 
chamber, acyldepsipeptides promote 
large-scale proteolysis in the dormant cell, making it impossible for the 
persister to come back to life. While this 
approach is no cure for the problem 
of antibiotic resistance, it bears the 
promise of overcoming pathogen 
resilience in some types of chronic and 
relapsing infections. 
One final remedy for bacterial 
infections that could conceivably 
provide a way out of the crisis 
surrounding antibiotics resistance is 
popular in the former Soviet republic 
of Georgia and in Poland, but virtually 
unknown in the rest of the world, to the 
extent that it isn’t even mentioned in 
the CDC report. This method is phage 
therapy, i.e. the use of bacteriophages 
to kill pathogenic bacteria (see Curr. 
Biol. (2011) 21, R267–R270). 
Pioneered in 1919 by one of the 
discoverers of bacteriophages, the 
French-Canadian microbiologist Felix 
d’Herelle, phage therapy fell into 
oblivion when antibiotics conquered 
the world. Now that antibiotics are in 
crisis due to their widespread misuse, 
phage therapy is experiencing a 
modest revival, expanding from its 
spiritual home in Tbilisi, Georgia. 
In Germany, for instance, Christine 
Rohde at the Leibniz Institute DSMZ 
(German Collection of Microrganisms 
and Cell Cultures) at Braunschweig 
looks after a collection already 
comprising over 350 strains of phages. 
The institute currently calls for university 
students to help as ‘phage trappers’ to 
extend their collection, with a view to 
use phages in medical research. 
The DSMZ has already collaborated 
with the phage institute in Tbilisi to 
develop phage cocktails against 
MRSA. Currently, the institute 
works on the characterisation of 
phages to fight bacteria of the order 
Burkholderiales, which play a role in 
the biofilms in the lungs of patients 
with COPD (chronically obstructive 
pulmonary disease) or cystic fibrosis. 
The institute also handles genomics 
and bioinformatics for the species 
collected, while the Helmholtz Centre 
for Infection Research nearby provides 
examination of phage morphology. 
Meanwhile, in France, Laurent 
Debarbieux and colleagues at the 
Pasteur Institute in Paris, where 
Felix d’Herelle discovered phages 
and conducted the first experiments 
for therapies, are also revisiting 
the medical potential of phages. 
Specifically, Debarbieux’s group is 
studying model systems of acute lung 
infections and of intestinal colonies. As phages are highly specialised to 
infect bacterial cells, it is extremely 
unlikely they could harm human cells 
when applied as therapy, and indeed 
no adverse side effects have been 
reported in Eastern Europe where 
phage cocktails have been applied for 
many decades. 
Problems standing in the way of 
formal recognition for phage therapy 
in western countries are more of a 
bureaucratic nature — phages are 
difficult to categorise, as they are 
neither molecules nor living beings as 
such, and hard to standardise, as they 
aren’t produced synthetically. 
With all these modest silver linings, 
it appears at least conceivable that the 
antibiotic apocalypse, i.e. the complete 
loss of the advantage that antibiotics 
have brought us in the second half of 
the 20th century, can still be averted. 
It would help, however, if authorities 
could finally stop the blatant misuse of 
antibiotics in agriculture and medicine. 
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